NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $4.49 +0.21 (+4.91%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.25▼$4.5150-Day Range$2.88▼$4.6852-Week Range$2.01▼$6.13Volume593,569 shsAverage Volume881,064 shsMarket Capitalization$367.24 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sutro Biopharma alerts: Email Address Sutro Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside178.4% Upside$12.50 Price TargetShort InterestBearish4.52% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment1.01Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.19) to ($3.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.01 out of 5 starsMedical Sector209th out of 936 stocksBiological Products, Except Diagnostic Industry27th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSutro Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Sutro Biopharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.52% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 14.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 3.3 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sutro Biopharma this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows8 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($3.19) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sutro Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Sutro Biopharma Stock (NASDAQ:STRO)Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More STRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STRO Stock News HeadlinesJuly 23, 2024 | finance.yahoo.comMeet Sutro: Brondell expands market reach with all-new, high-tech Integrated Smart Bidet ToiletJune 3, 2024 | prnewswire.comVGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipelineJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)May 15, 2024 | markets.businessinsider.comBuy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for LuveltaMay 14, 2024 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesMay 13, 2024 | msn.comSTRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | globenewswire.comSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 13, 2024 | finance.yahoo.comThe past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitableMay 8, 2024 | markets.businessinsider.comExpert Outlook: Sutro Biopharma Through The Eyes Of 10 AnalystsMay 8, 2024 | msn.comB of A Securities Initiates Coverage of Sutro Biopharma (STRO) with Buy RecommendationMay 8, 2024 | msn.comBofA starts Sutro at buy, cites ovarian cancer drug candidateApril 30, 2024 | globenewswire.comSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialApril 17, 2024 | msn.comSutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15April 3, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising PipelineApril 2, 2024 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 2, 2024 | markets.businessinsider.comIpsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln DealSee More Headlines Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+178.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,790,000.00 Net Margins-74.61% Pretax Margin-63.06% Return on Equity-94.18% Return on Assets-27.38% Debt Debt-to-Equity RatioN/A Current Ratio4.46 Quick Ratio4.46 Sales & Book Value Annual Sales$153.73 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book1.83Miscellaneous Outstanding Shares81,790,000Free Float76,968,000Market Cap$367.24 million OptionableOptionable Beta1.22 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. William J. Newell J.D. (Age 66)CEO & Director Comp: $1.06MDr. Hans-Peter Gerber Ph.D. (Age 61)Chief Scientific Officer Comp: $575.83kDr. Anne Elizabeth Borgman-Hagey M.D. (Age 56)Chief Medical Officer Comp: $848.98kMs. Jane Chung R.Ph. (Age 53)President & COO Comp: $934.64kDr. James R. Swartz DScPh.D., Sc.D., FounderMr. Edward C. Albini M.B.A (Age 66)CFO & Secretary Comp: $596.4kDr. Venkatesh Srinivasan Ph.d. (Age 62)Chief Technical Operations Officer Mr. David Pauling J.D.M.A., General CounselMs. Linda A. Fitzpatrick (Age 67)Chief People & Communications Officer Comp: $595.79kDr. Nicki Vasquez Ph.D. (Age 61)Chief Portfolio Strategy & Alliance Officer More ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSSana BiotechnologyNASDAQ:SANANurix TherapeuticsNASDAQ:NRIXDay One BiopharmaceuticalsNASDAQ:DAWNANI PharmaceuticalsNASDAQ:ANIPView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 88,034 shares on 7/26/2024Ownership: 0.333%SG Americas Securities LLCSold 6,421 shares on 7/12/2024Ownership: 0.018%Virtu Financial LLCBought 46,391 shares on 5/20/2024Ownership: 0.077%Jacobs Levy Equity Management Inc.Bought 729,239 shares on 5/16/2024Ownership: 1.713%California State Teachers Retirement SystemSold 3,776 shares on 5/16/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $4.29 on January 1st, 2024. Since then, STRO stock has increased by 4.7% and is now trading at $4.49. View the best growth stocks for 2024 here. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.92) by $0.03. The company had revenue of $13.01 million for the quarter, compared to analyst estimates of $11.57 million. Sutro Biopharma had a negative net margin of 74.61% and a negative trailing twelve-month return on equity of 94.18%. What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Top institutional investors of Sutro Biopharma include Bank of New York Mellon Corp (0.33%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Nicki Vasquez, William J Newell and Brunilda Shtylla. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA) and Provention Bio (PRVB). This page (NASDAQ:STRO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STRO Stock Alerts